Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. MGC Pharmaceuticals Limited
  6. News
  7. Summary
    MXC   AU000000MXC6

MGC PHARMACEUTICALS LIMITED

(MXC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MGC Pharmaceuticals Limited Completes Production of AUD 1 Million ArtemiC Order from SPC

11/24/2021 | 05:25pm EST

MGC Pharmaceuticals Ltd. confirmed that it has completed production of the ?650,000 (AUD 1,000,000) ArtemiCTM order from Swiss PharmaCan AG, as first announced on 4 May 2021. Under the terms of the contract, MGC Pharma expects to receive the full order amount of ?650,000 (AUD 1,000,000) by early December, which would place the Company on track to deliver its best quarter and half yearly revenue result as at 31 December 2021. MGC Pharma are the sole producer of ArtemiCTM and SPC, the master distributors. MGC Pharma has existing food supplement manufacturing capacity in Slovenia to produce this and future orders from SPC, which are progressing access to new markets following the September grant of the Certificate of Free Trade in Germany and the EU. MGC Pharma and SPC are continuing to seek approvals for ArtemiCTM as a supplement in a number of countries to provide support to COVID-19 patients and alleviate their symptoms. Alongside this, MGC Pharma are making progress on the long-term development of the Investigational Medicinal Product CimetrATM through its ongoing clinical studies, and applications for Emergency Use Authorisation in India and other National Regulatory and Medical Agencies are currently underway.


© S&P Capital IQ 2021
All news about MGC PHARMACEUTICALS LIMITED
01/13MGC PHARMACEUTICALS : General Meeting Notice of Meeting
PU
01/06MGC Pharmaceuticals Secures Import Approval for ArtemiC Rescue from Indian Regulators; ..
MT
01/06MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of Artem..
CI
01/06MGC Gets Indian Import Approval For COVID-19 Treatment; Shares Up 7%
MT
2021Glow LifeTech Announces Start of Clinical Study of Artemic Support Featuring MyCell Tec..
MT
2021Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmac..
CI
2021MGC Pharmaceuticals Begins Long COVID Study for Supplement Drug in Spain
MT
2021MGC PHARMACEUTICALS : Application for quotation of securities - MXC
PU
2021MGC Pharmaceuticals Limited announced that it has received ?5.5 million in funding
CI
2021Omicron Variant Seen Posing Threat to Pound
DJ
More news
Financials
Sales 2022 17,6 M 12,6 M 12,6 M
Net income 2022 -4,37 M -3,15 M -3,15 M
Net Debt 2022 7,90 M 5,68 M 5,68 M
P/E ratio 2022 -21,7x
Yield 2022 -
Capitalization 105 M 76,5 M 75,7 M
EV / Sales 2022 6,44x
EV / Sales 2023 3,67x
Nbr of Employees -
Free-Float 93,9%
Chart MGC PHARMACEUTICALS LIMITED
Duration : Period :
MGC Pharmaceuticals Limited Technical Analysis Chart | MXC | AU000000MXC6 | MarketScreener
Technical analysis trends MGC PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,04 AUD
Average target price 0,14 AUD
Spread / Average Target 259%
EPS Revisions
Managers and Directors
Roby Reuven Zomer Chief Executive Officer, Director & MD
Brett Anthony Mitchell Executive Chairman
Amir Polak Chief Technology Officer
Stephen B. Parker Senior Independent Director
Evan Hayes Independent Non-Executive Director